This article deals with CML, but what it raises may be the future of TKI use in CLL as well...
Will these new treatments simply be too expensive for use in 'socialized healthcare systems'?
Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML Experts
'As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing, their impact on individual patients and healthcare policies, and argues for the need to lower the prices of cancer drugs to allow more patients to afford them and to maintain sound long-term healthcare policies.'
'Of the 12 drugs approved by the FDA for various cancer indications in 2012, 11 were priced above $100,000 per year. Cancer drug prices have almost doubled from a decade ago, from an average of $5,000 per month to more than $10,000 per month.'
'In many countries, an additional year lived is judged to be “worth” about $50-100,000. In England, the National Institute for Health and Clinical Excellence (NICE) values a year lived at about 30,000 British pounds, or about $50,000.'
Hmmmmmmm...
bloodjournal.hematologylibr...
Edit
New York Times Article:
Interesting recently published overview of Chronic Lymphocytic Leukaemia and Hairy-Cell Leukaemia
Clinical trial results & reviews of new treatments for CLL written in easy to understand terms 
Ibrutinib Slow but steady foreward movement.
The Improvisational Oncologist - The New York Times
